This page shows the latest IL-13 inhibitor news and features for those working in and with pharma, biotech and healthcare.
The pharma giant is also set to gain an additional phase 3 candidate from the deal – lebrikizumab, a monoclonal antibody designed to bind to IL-13 that is being evaluated for ... Dermira gained the bulk of the rights to the IL-13 inhibitor in a
Atopic dermatitis was poorly-served with therapies for years, but latterly has seen new treatment options come to market including Sanofi and Regeneron’s IL-4 and IL-13 inhibitor Dupixent ... There are a number of drugs coming through the collective
Dupixent – an IL-4 and IL-13 inhibitor that is one of the fast-growing drugs in both Sanofi and Regeneron’s portfolios – is already approved in the US for atopic
The drug earned £152m ($193m) in Q1 this year (up 41% on the same period a year earlier) but is also facing competition from other IL-5 inhibitors including AstraZeneca’s ... Another significant challenger in the market is Sanofi's Dupixent, a dual
The dual IL-4 and IL-13 inhibitor has just gained approval for the new use in the European Union, and the partners are amassing data which shows it can alleviate
For Sanofi and its Dupixent (dupilumab) partner Regeneron, approval for the IL-4 and IL-13 inhibitor as an add-on maintenance treatment for severe asthma is also viewed as a ... AbbVie and Boehringer Ingelheim’s IL-23 inhibitor Skyrizi (risankizumab)
More from news
Approximately 1 fully matching, plus 22 partially matching documents found.
Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...